Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
We assessed the relationship between the serum levels of antibodies against double-stranded DNA (dsDNA), C1q, nucleosomes, histones, C3 and C4 complement components with one another, with organ involvement and overall disease activity in patients with systemic lupus erythematosus (SLE). One hundred seventy-five sera from 99 patients with SLE, 31 sera of patients with other connective tissue diseases, and 20 sera from healthy blood donors were tested. SLE disease activity was assessed by modified SLEDAI-2K (M-SLEDAI-2K), not including complement and anti-dsDNA descriptors. Anti-dsDNA antibodies were measured by indirect immunofluorescence on Crithidia luciliae (CLIFT), standard enzyme-linked immunosorbent assay (ELISA) and ELISA for high-avidity antibodies. The most significant risk factor for renal involvement were anti-C1q antibodies (OR = 3.88, p 5) (OR = 5.5, p < 0.01). The presence of high-avidity anti-dsDNA antibodies represented a risk for renal, joint, and most importantly for serosal involvement. Our results suggest that simple and reliable ELISA for high-avidity anti-dsDNA antibodies is the test of good clinical utility for the assessment of global SLE activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mainly assays that detect high avidity antibodies showed a correlation with disease activity or lupus nephritis [45], [58], [64].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [58]
In the citing paper
“| ELISA The Binding Site (Farrzyme) | 95.0 [90.2-96.0] | 52.0 [36.0-60.6] | 43, 45, 58 | |”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [58]
In the citing paper
“| Orgentec | 83.0 [78.4-96.5] | 82.6 [63.0-82.7] | 39, 45, 58 | |”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [58]
In the citing paper
“| ELISA The Binding Site (Farrzyme) | 95.0 [90.2-96.0] | 52.0 [36.0-60.6] | 43, 45, 58 | |”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [58]
In the citing paper
“| Orgentec | 83.0 [78.4-96.5] | 82.6 [63.0-82.7] | 39, 45, 58 | |”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [58]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 41 · Cited by 56
Metadata
- Authors
- Andrejevic, S., Jeremic, I., Sefik-Bukilica, M., Nikolic, M., Stojimirovic, B., & Bonaci-Nikolic, B.
- Affiliations
- University of Belgrade (RS)
- ORCID
- Nikolic, Milos
- Venue
- Clinical Rheumatology
- Published
- 2013-07-16
- Volume
- 32
- Issue
- 11
- Pages
- 1619-1626
- ISSN
- 0770-3198 (ISSN-L)
- 1434-9949
- OpenAlex
- W2006161397
- Cited by
- 56
- References
- 41
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 11 · 2020: 1 · 2019: 8 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 3 · 2014: 1 · 2013: 1
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical Rheumatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- systemic lupus erythematosus, disease activity, SLEDAI-2K, complement C3, anti-C1q antibodies, anti-histone antibodies, anti-nucleosome antibodies, renal involvement, polyserositis, connective tissue diseases, autoantibodies, risk factors
- MeSH terms
- Adolescent, Adult, Aged, Autoantibodies, Complement System Proteins, DNA, Enzyme-Linked Immunosorbent Assay, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Severity of Illness Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. https://app.cochat.ai/papers/10.1007/s10067-013-2330-3
- The paper
- Andrejevic, S., Jeremic, I., Sefik-Bukilica, M., Nikolic, M., Stojimirovic, B., & Bonaci-Nikolic, B. (2013). Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. Clinical Rheumatology. https://doi.org/10.1007/s10067-013-2330-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.